Regular Article CLINICAL TRIALS AND OBSERVATIONS A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma
نویسندگان
چکیده
A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma Paul G. Richardson, Wanling Xie, Sundar Jagannath, Andrzej Jakubowiak, Sagar Lonial, Noopur S. Raje, Melissa Alsina, Irene M. Ghobrial, Robert L. Schlossman, Nikhil C. Munshi, Amitabha Mazumder, David H. Vesole, Jonathan L. Kaufman, Kathleen Colson, Mary McKenney, Laura E. Lunde, John Feather, Michelle E. Maglio, Diane Warren, Dixil Francis, Teru Hideshima, Robert Knight, Dixie-Lee Esseltine, Constantine S. Mitsiades, Edie Weller, and Kenneth C. Anderson
منابع مشابه
Regular Article CLINICAL TRIALS AND OBSERVATIONS PANORAMA 2: panobinostat in combination with bortezomib and dexamethasone in patients with relapsed and bortezomib-refractory myeloma
Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA; H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL; The University of Texas MD Anderson Cancer Center, Houston, TX; Stanford Cancer Center and Stanford University School of Medicine, Palo Alto, CA; Duke University Medical Center, Durham, NC; Novartis Pharmaceuticals Corporation, East Hanover, NJ; and Winship Cancer Inst...
متن کاملCLINICAL TRIALS AND OBSERVATIONS Combination of bendamustine, lenalidomide, and dexamethasone (BLD) in patients with relapsed or refractory multiple myeloma is feasible and highly effective: results of phase 1/2 open-label, dose escalation study
1Department of Medicine, Division of Hematology/Oncology, University of Pittsburgh School of Medicine and Cancer Institute, Pittsburgh, PA; 2Myeloma Program, Karmanos Cancer Institute, Detroit, MI; 3University of Pittsburgh Medical Center Cancer Centers, Pittsburgh, PA; 4Biostatistics Facility, University of Pittsburgh Cancer Institute, University of Pittsburgh, Pittsburgh, PA; and 5College of ...
متن کاملCLINICAL TRIALS AND OBSERVATIONS Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure
1Department of Lymphoma and Myeloma, M. D. Anderson Cancer Center, Houston, TX; 2Department of Clinical Therapeutics, University of Athens School of Medicine, Athens, Greece; 3Department of Medicine, Princess Margaret Hospital, Toronto, ON; 4Hematology Department, Institute of Hematology and Oncology, Hospital Clinic, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universit...
متن کاملCLINICAL TRIALS AND OBSERVATIONS Lenalidomide, adriamycin, and dexamethasone (RAD) in patients with relapsed and refractory multiple myeloma: a report from the German Myeloma Study Group DSMM (Deutsche Studiengruppe Multiples Myelom)
1Department of Internal Medicine II, Division of Hematology and Medical Oncology, University Hospital Wuerzburg and Early Clinical Development Unit of Comprehensive Cancer Center Mainfranken (CCCM), Wuerzburg; 2Department of Hematology/Oncology, HELIOS Klinikum Berlin Buch, Berlin; 3Department of Internal Medicine III, University Hospital, Ulm; 4Medizinische Klinik und Poliklinik I, Universität...
متن کاملCLINICAL TRIALS AND OBSERVATIONS Clinical factors predictive of outcome with bortezomib in patients with relapsed, refractory multiple myeloma
Bortezomib, a potent and reversible proteasome inhibitor, affects the myeloma cell and its microenvironment, resulting in downregulation of growth and survival signaling pathways and durable responses in patients with relapsed and refractory myeloma. Potential associations between baseline parameters and outcomes with bortezomib were explored in 202 patients who received bortezomib 1.3 mg/m2 tw...
متن کامل